BioCardia Will Present Heart Failure Trial in Phoenix
Researchers will share trial design details for an experimental cell therapy for patients with reduced ejection fraction.
Updated on Oct. 8, 2026 in Heart Disease
Live Poll
Should the FDA fast-track approval for experimental cell therapies to treat chronic heart failure?
BioCardia will present the design for its CardiAMP HF II trial at the Heart Failure Society of America Annual Scientific Meeting in Phoenix, running from October 9 to October 12, 2026. This trial investigates a new approach for patients currently living with ischemic heart failure and reduced ejection fraction.
Why it matters
The study aims to determine the efficacy of high-dose autologous cell treatment as a potential add-on for patients already on standard guideline-directed medical therapy. The findings are intended to support future regulatory submissions to both the FDA and Japan's PMDA.
The CardiAMP HF II study is a clinical investigation evaluating high-dose autologous cell treatment in patients with ischemic heart failure and reduced ejection fraction. The trial results are intended to provide evidence for regulatory approval, though clinical data remains pending.
The players
BioCardia
A biotechnology company based in Sunnyvale, California, focused on the development of regenerative heart failure therapies.
Heart Failure Society of America
A professional organization of scientists and clinicians dedicated to the advancement of heart failure research and patient care.
The details
The experimental therapy involves harvesting a patient's own cells, which are then processed and delivered back to the heart muscle to potentially improve function. This autologous approach aims to augment current guideline-directed medical therapies in patients with reduced ejection fraction. The FDA has granted a category B designation to the underlying cell therapy system across three clinical trials, reflecting its status as an investigational medical device.
Timeline
March 24, 2026: BioCardia filed its Form 10-K with the SEC.
October 7, 2026: BioCardia announced the upcoming scientific poster presentation.
October 9 - 12, 2026: The HFSA Annual Scientific Meeting takes place in Phoenix.
Health Landscape
This development follows the arc of regenerative medicine research aimed at addressing ischemic heart failure. It represents a pivot toward investigating whether autologous cell-based interventions can meaningfully improve outcomes for patients already receiving optimized medical therapy.
This trial is currently in the development stage and is not a treatment available for clinical use. Patients with ischemic heart failure should continue to consult with their cardiologist regarding established, evidence-based management options like guideline-directed medical therapy.
The takeaway
The CardiAMP HF II trial is exploring whether harvesting a patient's own cells can aid in heart repair for those with reduced ejection fraction. Patients should track their heart failure management plan with their physician and stay informed on new clinical data as it is published.
Further reading
For more information on current treatment protocols, visit the Heart Disease section.
More information
Learn more about ongoing research and company updates on the BioCardia company website.
Live Poll
Should the FDA fast-track approval for experimental cell therapies to treat chronic heart failure?
